Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
76 participants
INTERVENTIONAL
2017-09-12
2019-08-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Erythropoietin
500 IU/kg of EPO given intramuscularly 3 times for each patient
Erythropoietin
500 IU/kg of erythropoietin is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
Control
Same amount of normal saline given intramuscularly 3 times for each patient
normal saline
The same amount of normal saline is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Erythropoietin
500 IU/kg of erythropoietin is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
normal saline
The same amount of normal saline is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients scheduled for elective total knee arthroplasty, total hip arthroplasty
Exclusion Criteria
* Cognitive impairment
* Unable to pre-screen delirium due to underlying central nervous system disease
* History of hypersensitivity related to erythropoietin and other anesthesia-related drugs
* History of myocardial infarction, pulmonary infarction, cerebral infarction, ischemic vascular disease, epilpesy, chronic liver disease, chronic kidney disease
* Uncontrolled high blood pressure
* Within one month of starting anti-hypertensive medication
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yonsei University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bon-Nyeo Koo
Role: PRINCIPAL_INVESTIGATOR
Department of Anesthesiology and Pain medicine, Severance Hospital, Seoul, South Korea
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Anesthesiology and Pain medicine, Severance Hospital, Seoul, South Korea
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kim EJ, Park KK, Choi SY, Ju HM, Kim TL, Kim J, Kim SY, Koo BN. Erythropoietin for the prevention of postoperative neurocognitive disorder in older adult patients undergoing total joint arthroplasty: a randomized controlled study. BMC Anesthesiol. 2024 Nov 15;24(1):418. doi: 10.1186/s12871-024-02770-9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4-2017-0694
Identifier Type: -
Identifier Source: org_study_id